Crescendo Biologics, Theodora Harold

Crescendo Biologics, a biotech based in Cambridge, UK, has promoted Theodora Harold to the position of CEO, previously she held the position of CFO. The move was made due to the current CEO, Peter Pack, stepping down from the role – with him due to leave the position on May 1 but remaining as a senior advisor to the company.

Harold has worked at the company since 2016, joining the company as CFO. Prior to Crescendo, she worked at PsiOxus Therapeutics for seven years in the same position.

Kevin Johnson, non-executive chairman of Crescendo Biologics, said, “The decision to appoint Harold to succeed Pack was a straightforward and a unanimous one because of her in-depth knowledge of the business and industry as a whole. She has worked tirelessly to build the business so far and she has exciting ambitions for the company in the longer term.”​

Crescendo is developing investigational therapeutics within oncology, particularly focusing on targeted T-cell activation. Its lead candidate is CB307, which is a bispecific PSMA-targeted T-cell engager – according to Harold, the candidate is on track to enter Phase I testing in 2020.